{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:45:39Z","timestamp":1782780339017,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG019134"],"award-info":[{"award-number":["AG019134"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11606-025-09691-4","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T13:43:45Z","timestamp":1751291025000},"page":"499-505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescribing GLPs for Obesity Treatment for Adults at a University Based Health Maintenance Organization by Race, Ethnicity, and Socioeconomic Status"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1049-9274","authenticated-orcid":false,"given":"Alissa S.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen E.","family":"Canavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasia J.","family":"Lipska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Richey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline S.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Zarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"9691_CR1","unstructured":"Centers for Disease Control and Prevention. Adult Obesity Facts. Accessed August 2, 2024, https:\/\/www.cdc.gov\/obesity\/php\/data-research\/adult-obesity-facts.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/obesity\/data\/adult.html"},{"issue":"3","key":"9691_CR2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMra1514009","volume":"376","author":"SB Heymsfield","year":"2017","unstructured":"Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. New England Journal of Medicine. 2017;376(3):254-266. https:\/\/doi.org\/10.1056\/NEJMra1514009","journal-title":"New England Journal of Medicine."},{"issue":"11","key":"9691_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"New England Journal of Medicine."},{"issue":"1","key":"9691_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015;373(1):11-22. https:\/\/doi.org\/10.1056\/NEJMoa1411892","journal-title":"New England Journal of Medicine."},{"issue":"3","key":"9691_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. https:\/\/doi.org\/10.1056\/NEJMoa2206038","journal-title":"New England Journal of Medicine."},{"issue":"24","key":"9691_CR6","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24):2221-2232. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"New England Journal of Medicine."},{"issue":"10278","key":"9691_CR7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/s0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. Mar 13 2021;397(10278):971-984. https:\/\/doi.org\/10.1016\/s0140-6736(21)00213-0","journal-title":"Lancet."},{"issue":"7","key":"9691_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. Aug 18 2015;314(7):687-99. https:\/\/doi.org\/10.1001\/jama.2015.9676","journal-title":"JAMA."},{"issue":"10402","key":"9691_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/s0140-6736(23)01200-x","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. Aug 19 2023;402(10402):613-626. https:\/\/doi.org\/10.1016\/s0140-6736(23)01200-x","journal-title":"Lancet."},{"issue":"13","key":"9691_CR10","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. 2024;391(13):1193-1205. https:\/\/doi.org\/10.1056\/NEJMoa2404881","journal-title":"New England Journal of Medicine."},{"issue":"6","key":"9691_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1215\/03616878-10041135","volume":"47","author":"R Chalasani","year":"2022","unstructured":"Chalasani R, Krishnamurthy S, Suda KJ, Newman TV, Delaney SW, Essien UR. Pursuing Pharmacoequity: Determinants, Drivers, and Pathways to Progress. J Health Polit Policy Law. Dec 1 2022;47(6):709-729. https:\/\/doi.org\/10.1215\/03616878-10041135","journal-title":"J Health Polit Policy Law."},{"issue":"7","key":"9691_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.2021.9907","volume":"326","author":"S Mahajan","year":"2021","unstructured":"Mahajan S, Caraballo C, Lu Y, et al. Trends in Differences in Health Status and Health Care Access and Affordability by Race and Ethnicity in the United States, 1999-2018. JAMA. 2021;326(7):637-648. https:\/\/doi.org\/10.1001\/jama.2021.9907","journal-title":"JAMA."},{"issue":"12","key":"9691_CR13","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1001\/jamacardio.2018.3945","volume":"3","author":"UR Essien","year":"2018","unstructured":"Essien UR, Holmes DN, Jackson LR, II, et al. Association of Race\/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiology. 2018;3(12):1174-1182. https:\/\/doi.org\/10.1001\/jamacardio.2018.3945","journal-title":"JAMA Cardiology."},{"issue":"10","key":"9691_CR14","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1158\/2159-8290.Cd-20-0941","volume":"10","author":"DR Rivera","year":"2020","unstructured":"Rivera DR, Peters S, Panagiotou OA, et al. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discov. Oct 2020;10(10):1514-1527. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0941","journal-title":"Cancer Discov."},{"issue":"3","key":"9691_CR15","first-page":"308","volume":"22","author":"H Zhang","year":"2012","unstructured":"Zhang H, Rodriguez-Monguio R. Racial disparities in the risk of developing obesity-related diseases: a cross-sectional study. Ethn Dis. Summer 2012;22(3):308-16.","journal-title":"Ethn Dis. Summer"},{"issue":"5","key":"9691_CR16","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/dom.15473","volume":"26","author":"H Gasoyan","year":"2024","unstructured":"Gasoyan H, Pfoh ER, Schulte R, Sullivan E, Le P, Rothberg MB. Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills. Diabetes Obes Metab. May 2024;26(5):1687-1696. https:\/\/doi.org\/10.1111\/dom.15473","journal-title":"Diabetes Obes Metab."},{"key":"9691_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.4735","author":"C Kim","year":"2025","unstructured":"Kim C, Ross JS, Jastreboff AM, et al. Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US. JAMA. 2025; https:\/\/doi.org\/10.1001\/jama.2025.4735","journal-title":"JAMA."},{"key":"9691_CR18","doi-asserted-by":"publisher","unstructured":"Shahzad M, Upshur R, Donnelly P, et al. A population-based approach to integrated healthcare delivery: a scoping review of clinical care and public health collaboration. BMC Public Health. 2019\/06\/07 2019;19(1):708. https:\/\/doi.org\/10.1186\/s12889-019-7002-z","DOI":"10.1186\/s12889-019-7002-z"},{"key":"9691_CR19","unstructured":"Centers for Disease Control and Prevention. Health Maintenance Organization (HMO). Updated August 12, 2022. Accessed November 8, 2024, https:\/\/www.cdc.gov\/nchs\/hus\/sources-definitions\/hmo.htm"},{"key":"9691_CR20","doi-asserted-by":"publisher","unstructured":"Kind AJ, Jencks S, Brock J, et al. Neighborhood Socioeconomic Disadvantage and 30-Day Rehospitalization. Annals of Internal Medicine. 2014;161(11):765-774. https:\/\/doi.org\/10.7326\/m13-2946 %m 25437404","DOI":"10.7326\/m13-2946"},{"issue":"5","key":"9691_CR21","doi-asserted-by":"publisher","first-page":"e035376","DOI":"10.1136\/bmjopen-2019-035376","volume":"10","author":"S Kurani","year":"2020","unstructured":"Kurani S, McCoy RG, Inselman J, et al. Place, poverty and prescriptions: a cross-sectional study using Area Deprivation Index to assess opioid use and drug-poisoning mortality in the USA from 2012 to 2017. BMJ Open. 2020;10(5):e035376. https:\/\/doi.org\/10.1136\/bmjopen-2019-035376","journal-title":"BMJ Open."},{"issue":"1","key":"9691_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/2193-1801-2-222","volume":"2","author":"Y Dong","year":"2013","unstructured":"Dong Y, Peng CY. Principled missing data methods for researchers. Springerplus. Dec 2013;2(1):222. https:\/\/doi.org\/10.1186\/2193-1801-2-222","journal-title":"Springerplus."},{"issue":"1","key":"9691_CR23","doi-asserted-by":"publisher","first-page":"i","DOI":"10.1002\/j.2333-8504.1975.tb01053.x","volume":"1975","author":"DB Rubin","year":"1975","unstructured":"Rubin DB. Inference and Missing Data. ETS Research Bulletin Series. 1975;1975(1):i-19. https:\/\/doi.org\/10.1002\/j.2333-8504.1975.tb01053.x","journal-title":"ETS Research Bulletin Series."},{"key":"9691_CR24","doi-asserted-by":"publisher","unstructured":"Yeo YH, Rezaie A, Hsieh TY-J, et al. Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis. Annals of Internal Medicine. 2024;177(9):1289\u20131291. https:\/\/doi.org\/10.7326\/m24-0019 %m 39038291","DOI":"10.7326\/m24-0019"},{"issue":"12","key":"9691_CR25","doi-asserted-by":"publisher","first-page":"e214182","DOI":"10.1001\/jamahealthforum.2021.4182","volume":"2","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Essien UR, et al. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum. Dec 2021;2(12):e214182. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.4182","journal-title":"JAMA Health Forum."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09691-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-09691-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09691-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:01:50Z","timestamp":1782777710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-09691-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["9691"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-09691-4","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"Dr. Lipska receives support from CMS to develop and evaluate publicly reported quality measures and royalties from UpToDate to write and edit content.Dr. Ross currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Agency for Healthcare Research and Quality (R01HS022882), and from Arnold Ventures;\u00a0formerly received research support from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST); and in addition, Dr. Ross was an expert witness at the request of Relator's attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc. that was settled September 2022.Dr. Chen, Ms. Brunetto, Dr. Canavan, Dr. Richey, Dr. Wilson, and Mr. Zarro have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest:"}},{"value":"Yale University Internal Review Board deemed this research to be exempt and granted a full waiver of HIPAA authorization.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate:"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}